# Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

> **NCT00080899** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer

## Interventions

- **DRUG:** fenretinide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00080899
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080899, "Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00080899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*